EUVIMEDEUVIMED entdecken
Crossref

Cryoablation for Treatment of Early-Stage Breast Cancer: Efficacy and Quality of Life Assessment

Jacopo Nori Cucchiari, Federica Di Naro, Giuliano Migliaro, Sofia Elisabetta Baldi Giorgi, Francesca Pugliese, Tommaso Amadori, Giulia Bicchierai, Diego De Benedetto, Chiara Bellini, Sofia Vidali, Ermanno Vanzi, Cecilia Boeri und 3 weitere

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2025.12.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Jacopo Nori Cucchiari und 14 weiteren Autor:innen. Beteiligte Einrichtung: Breast Diagnostic Unit - Careggi University Hospital, Florence, Italy. Hauptthemen laut MEDLINE: Cryosurgery, Breast Neoplasms, Quality of Life, Carcinoma, Ductal, Breast. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Breast cancer (BC) is the most common cancer among women. There has been growing interest in less invasive techniques for the treatment of breast lesions, with cryoablation emerging as promising option. We aimed to assess the safety and efficacy of cryoablation for the treatment of breast cancer tumor subtypes 12 months post-treatment. METHODS: This single-center prospective study included patients with biopsy-proven BC who underwent ultrasound-guided-cryoablation treatment during 2021-2023. Locoregional staging was performed using ultrasound and contrast-enhanced mammography (CEM). Follow-up included ultrasound at 1-, 3-, 6- and 12-months with additional CEM and biopsy at 12-months. Rate of complete ablation, tumor size and quality of life (QoL) were assessed. Primary endpoint was absence of residual tumor for BC at 12-month post cryoablation. RESULTS: Thirthy-six female patients (mean age, 84.5±6.7 years) with 39 biopsy-proven tumors (mean size 15.3±7.5 mm) underwent cryoablation. No device-related unexpected adverse events were reported. The 39 BCs were early-stage luminal A or B, invasive ductal carcinoma (IDC) or IDC + ductal carcinoma in situ. Complete ablation rates for BC ≤ 15 mm and BC >15 mm were 100% and 84.6%, respectively; Cryoablation positively impacted patient QoL as assessed by validated questionnaires. CONCLUSIONS: With improved QoL, cryoablation emerges as a promising, safe, and effective treatment option for low-risk breast cancer. DISCLAIMER/PUBLISHER'S NOTE: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CryosurgeryBreast NeoplasmsQuality of LifeCarcinoma, Ductal, BreastHumansFemaleProspective StudiesAged, 80 and overNeoplasm StagingAgedTreatment Outcome

Stichwörter der Autor:innen

AnxietyCEMEffectivenessLocal-controlOutcomes

Autor:innen und Institutionen

  • Breast Diagnostic Unit - Careggi University Hospital, Florence, Italy.
  • Breast Diagnostic Unit - Careggi University Hospital, Florence, Italy. Electronic address: federicanarella@gmail.com.
  • Department of Emergency Radiology, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy.
  • Breast Unit, Gynecology Section, Department of Health Sciences, University of Florence, Florence, Italy. Electronic address: tommaso.susini@unifi.it.

Zitieren

APA

Nori Cucchiari, J., Di Naro, F., Migliaro, G., Baldi Giorgi, S. E., Pugliese, F., Amadori, T., Bicchierai, G., De Benedetto, D., Bellini, C., Vidali, S., Vanzi, E., Boeri, C., Lamagna, V., Miele, V., & Susini, T. (2026). Cryoablation for Treatment of Early-Stage Breast Cancer: Efficacy and Quality of Life Assessment. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.12.004

Vancouver

Nori Cucchiari J, Di Naro F, Migliaro G, Baldi Giorgi SE, Pugliese F, Amadori T, et al. Cryoablation for Treatment of Early-Stage Breast Cancer: Efficacy and Quality of Life Assessment. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.12.004

BibTeX
@article{NoriCucchiari2026,
  author = {Nori Cucchiari, Jacopo and Di Naro, Federica and Migliaro, Giuliano and Baldi Giorgi, Sofia Elisabetta and Pugliese, Francesca and Amadori, Tommaso and Bicchierai, Giulia and De Benedetto, Diego and Bellini, Chiara and Vidali, Sofia and Vanzi, Ermanno and Boeri, Cecilia and Lamagna, Verdiana and Miele, Vittorio and Susini, Tommaso},
  title = {Cryoablation for Treatment of Early-Stage Breast Cancer: Efficacy and Quality of Life Assessment},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2025.12.004}
}
Kostenlos starten →